Filter Results
:
(269)
Show Results For
-
All HBS Web
(1,499)
- Faculty Publications (269)
Show Results For
-
All HBS Web
(1,499)
- Faculty Publications (269)
Page 1 of
269
Results
→
- 2024
- Working Paper
Does Private Equity Have Any Business Being in the Health Care Business?
By: Nori Gerardo Lietz and Zirui Song
Private Equity (“PE”) has come under increased scrutiny by the press, academics, and policymakers, as well as the public, for its investments in health care delivery. This scrutiny has been exacerbated by recent high profile hospital bankruptcies following PE...
View Details
Lietz, Nori Gerardo, and Zirui Song. "Does Private Equity Have Any Business Being in the Health Care Business?" Harvard Business School Working Paper, No. 25-012, September 2024.
- July 2024
- Case
Roja Garimella: Developing a Founder's Judgment
By: Reza Satchu and Patrick Sanguineti
Roja Garimella’s path to becoming a founder was anything but straight. Setting her sights on a career in medicine since childhood, she committed to medical school with her acceptance to college. And yet, throughout her studies, she continually explored alternative...
View Details
- June 2024
- Supplement
Legacy Partners (A)
By: Richard S. Ruback and Royce Yudkoff
Instructors should consider the timing of making videos available to students, as they may reveal key case details.
Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021.... View Details
Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021.... View Details
Keywords:
Acquisition;
Small Business;
Cost vs Benefits;
Decisions;
Corporate Entrepreneurship;
Leadership Style;
Leading Change;
Business or Company Management;
Problems and Challenges;
Health Care and Treatment;
Health Disorders;
Medical Specialties;
Nutrition;
Supply Chain Management;
Growth Management;
Health Industry;
Health Industry;
Health Industry;
United States;
California
Ruback, Richard S., and Royce Yudkoff. "Legacy Partners (A)." Harvard Business School Multimedia/Video Supplement 224-725, June 2024.
- June 2024
- Supplement
Legacy Partners (B)
By: Richard S. Ruback and Royce Yudkoff
Pre-abstract: Instructors should consider the timing of making videos available to students, as they may reveal key case details.
Abstract: Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months...
View Details
Keywords:
Acquisition;
Small Business;
Cost vs Benefits;
Decisions;
Business Education;
Corporate Entrepreneurship;
Leadership Style;
Leading Change;
Business or Company Management;
Problems and Challenges;
Health Care and Treatment;
Health Disorders;
Medical Specialties;
Nutrition;
Supply Chain Management;
Growth Management;
Health Industry;
Health Industry;
United States;
California
Ruback, Richard S., and Royce Yudkoff. "Legacy Partners (B)." Harvard Business School Multimedia/Video Supplement 224-726, June 2024.
- May 2024
- Supplement
DRSi (A)
By: Richard S. Ruback and Royce Yudkoff
In March of 2019, Jen Ransom Fuller purchased DRSi. DRSi, located in Bellevue, Washington, printed and reproduced architectural plans and drawings. Fuller planned to use her first year of ownership to learn the business and to run it in much the same way as the seller....
View Details
Keywords:
Acquisition;
Small Business;
Cost vs Benefits;
Decisions;
Business Education;
Corporate Entrepreneurship;
Leadership Style;
Leading Change;
Business or Company Management;
Problems and Challenges;
Health Pandemics;
Selection and Staffing;
Employee Relationship Management;
Production;
Logistics;
Safety;
United States;
Washington (state, US)
Ruback, Richard S., and Royce Yudkoff. " DRSi (A)." Harvard Business School Multimedia/Video Supplement 224-717, May 2024.
- May 2024
- Supplement
DRSi (B)
By: Richard S. Ruback and Royce Yudkoff
Pre-Abstract: Instructors should consider the timing of making videos available to students, as they may reveal key case details.
Abstract: In March of 2019, Jen Ransom Fuller purchased DRSi. DRSi, located in Bellevue, Washington, printed and reproduced... View Details
Abstract: In March of 2019, Jen Ransom Fuller purchased DRSi. DRSi, located in Bellevue, Washington, printed and reproduced... View Details
Keywords:
Acquisition;
Small Business;
Cost vs Benefits;
Decisions;
Business Education;
Corporate Entrepreneurship;
Leadership Style;
Leading Change;
Business or Company Management;
Problems and Challenges;
Health Pandemics;
Selection and Staffing;
Employee Relationship Management;
Production;
Logistics;
Safety;
Washington (state, US);
United States
Ruback, Richard S., and Royce Yudkoff. " DRSi (B)." Harvard Business School Multimedia/Video Supplement 224-718, May 2024.
- May 2024
- Article
True Costs of Uterine Artery Embolization: Time-Driven Activity-Based Costing in Interventional Radiology Over a 3-Year Period
By: Julia C. Bulman, Nicole H. Kim, Robert S. Kaplan, Sarah Schroeppel DeBacker, Olga R. Brook and Ammar Sarwar
The study used time-driven activity-based costing (TDABC) to estimate the costs to perform uterine artery embolization (UAE). Utilization times for patients undergoing outpatient UAE for fibroids or adenomyosis were captured from electronic health record timestamps and...
View Details
Bulman, Julia C., Nicole H. Kim, Robert S. Kaplan, Sarah Schroeppel DeBacker, Olga R. Brook, and Ammar Sarwar. "True Costs of Uterine Artery Embolization: Time-Driven Activity-Based Costing in Interventional Radiology Over a 3-Year Period." Journal of the American College of Radiology 21, no. 5 (May 2024): 721–728.
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of...
View Details
Keywords:
Cost vs Benefits;
Decisions;
Judgments;
Values and Beliefs;
Global Strategy;
Health Care and Treatment;
Patents;
Growth and Development Strategy;
Growth Management;
Product Positioning;
Supply and Industry;
Supply Chain;
Corporate Social Responsibility and Impact;
Mission and Purpose;
Philanthropy and Charitable Giving;
Opportunities;
Social Issues;
Equality and Inequality;
Health Industry;
Health Industry;
Denmark;
United States;
Europe;
China;
India;
Middle East;
North Africa
Badaracco, Joseph L., Tom Quinn, and John Schultz. "Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs." Harvard Business School Case 324-114, April 2024. (Revised July 2024.)
- March 2024
- Article
Do Safety Management System Standards Indicate Safer Operations? Evidence from the OHSAS 18001 Occupational Health and Safety Standard
By: Kala Viswanathan, Matthew S. Johnson and Michael W. Toffel
Problem definition: Given the enormous disruptions and costs of occupational injuries, companies and buyers are increasingly looking to voluntary occupational health and safety standards to improve worker safety. Yet because these standards only require...
View Details
Keywords:
Occupational Health;
Occupational Safety;
Program Evaluation;
Safety Performance;
Injuries;
OHSAS 18001;
ISO 45001;
Working Conditions;
Safety;
Standards
Viswanathan, Kala, Matthew S. Johnson, and Michael W. Toffel. "Do Safety Management System Standards Indicate Safer Operations? Evidence from the OHSAS 18001 Occupational Health and Safety Standard." Art. 106383. Safety Science 171 (March 2024).
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that...
View Details
Keywords:
Policy;
Government Legislation;
Health Care and Treatment;
Negotiation;
Price;
Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- January 19, 2024
- Article
Value-Based Health Care Can Transform the Treatment of Patients with Substance Use Disorder
By: Robert S. Kaplan and Sarah E. Wakeman
U.S. overdose deaths currently exceed 100,000 per year. New facilities, known as bridge clinics, are broadening access to high-quality care by offering outpatient substance use disorder (SUD) treatment with few access barriers. But many of the critical services offered...
View Details
Kaplan, Robert S., and Sarah E. Wakeman. "Value-Based Health Care Can Transform the Treatment of Patients with Substance Use Disorder." Health Affairs Forefront (January 19, 2024).
- January 2024
- Article
A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder
By: Sarah E. Wakeman, Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe and Robert S. Kaplan
The US fee-for-service payment system under-reimburses clinics offering access to comprehensive treatments for opioid use disorder (OUD). The funding shortfall limits a clinic’s ability to expand and improve access, especially for socially marginalized patients with...
View Details
Wakeman, Sarah E., Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe, and Robert S. Kaplan. "A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder." Journal of Behavioral Health Services & Research 51, no. 1 (January 2024): 22–30.
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
Vogel, Matthew, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim, and Benjamin N. Rome. "Cost of Exempting Sole Orphan Drugs from Medicare Negotiation." JAMA Internal Medicine 184, no. 1 (January 2024): 63–69.
- 2023
- Working Paper
Are Hospital Quality Indicators Causal?
By: Amitabh Chandra, Maurice Dalton and Douglas O. Staiger
Hospitals play a key role in patient outcomes and spending, but efforts to improve their quality are hindered because we do not know whether hospital quality indicators are causal or biased. We evaluate the validity of commonly used quality indicators, such as...
View Details
Keywords:
Quality;
Health Care and Treatment;
Measurement and Metrics;
Outcome or Result;
Health Industry
Chandra, Amitabh, Maurice Dalton, and Douglas O. Staiger. "Are Hospital Quality Indicators Causal?" NBER Working Paper Series, No. 31789, October 2023.
- October 2023
- Article
Health System Perspective on Cost for Delivering a Decision Aid for Prostate Cancer Using Time-Driven Activity-Based Costing
By: David R. Ho, Robert S. Kaplan, Jonathan Bergman, David F. Penson, Benjamin Waterman, Kristin C. Williams, Jefersson Villatoro, Lorna Kwan and Christopher S. Saigal
Previsit decision aids (DAs) have been shown to improve decisional quality. But the cost to deploy a DA has not been previously estimated. We interviewed or observed relevant personnel at three institutions that had implemented DA programs for men with prostate cancer....
View Details
Keywords:
Time-Driven Activity-Based Costing;
Health Care and Treatment;
Cost Accounting;
Health Industry
Ho, David R., Robert S. Kaplan, Jonathan Bergman, David F. Penson, Benjamin Waterman, Kristin C. Williams, Jefersson Villatoro, Lorna Kwan, and Christopher S. Saigal. "Health System Perspective on Cost for Delivering a Decision Aid for Prostate Cancer Using Time-Driven Activity-Based Costing." Medical Care 61, no. 10 (October 2023): 681–688.
- September–October 2023
- Article
Prospective Evaluation of the Cost of Performing Breast Imaging Examinations Using Time-Driven Activity-Based Costing Method: A Single Center Study
By: Aamir Ali, Jordana Phillips, Damir Ljuboja, Syed S. Shehab, Etta D. Pisano, Robert S. Kaplan and Ammar Sarwar
We use time-driven activity-based costing (TDABC) to measure the cost of performing breast imaging using different modalities: full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), US and MRI exams, and...
View Details
Keywords:
Time-Driven Activity-Based Costing;
Health Care;
Breast Cancer;
Health Care and Treatment;
Cost;
Cost Accounting;
Health Industry
Ali, Aamir, Jordana Phillips, Damir Ljuboja, Syed S. Shehab, Etta D. Pisano, Robert S. Kaplan, and Ammar Sarwar. "Prospective Evaluation of the Cost of Performing Breast Imaging Examinations Using Time-Driven Activity-Based Costing Method: A Single Center Study." Journal of Breast Imaging 5, no. 5 (September–October 2023): 546–554.
- September 2023
- Article
The Health Costs of Dirty Energy: Evidence from the Capacity Market in Colombia
By: Achyuta Adhvaryu, Theresa Molina, Anant Nyshadham, Jorge Tamayo and Nicholas Torres
The health effects of “dirty” (fossil fuel driven) energy production are difficult to measure accurately due to the endogeneity of fuel choice. We exploit an electricity policy in Colombia that generates a price-based trigger for the use of thermal energy sources....
View Details
Adhvaryu, Achyuta, Theresa Molina, Anant Nyshadham, Jorge Tamayo, and Nicholas Torres. "The Health Costs of Dirty Energy: Evidence from the Capacity Market in Colombia." Art. 103116. Journal of Development Economics 164 (September 2023).
- October 2023
- Article
What Does the Inflation Reduction Act Mean for Patients and Physicians?
By: Amitabh Chandra and Benedic Ippolito
The debate around prescription drug measures in the recently passed U.S. Inflation Reduction Act (IRA), which limit some patients’ out-of-pocket costs, has not fully addressed their effect on physicians and patients via their effect on payers. Reducing patients’ costs...
View Details
Chandra, Amitabh, and Benedic Ippolito. "What Does the Inflation Reduction Act Mean for Patients and Physicians?" NEJM Catalyst Innovations in Care Delivery 4, no. 10 (October 2023).
- July–August 2023
- Article
Investing in Growth Through Uncertainty
By: Ranjay Gulati
When faced with disruptions and downturns, many leaders and companies instinctively focus on cutting costs to maintain profitability. But some identify opportunities and then take thoughtful action to emerge from crisis even stronger. That means not only planning for...
View Details
Gulati, Ranjay. "Investing in Growth Through Uncertainty." Harvard Business Review 101, no. 4 (July–August 2023): 36–42.
- April 2023 (Revised January 2024)
- Background Note
Note on Healthcare in Ghana
By: Regina E. Herzlinger and Ben Creo
This note provides an overview of the healthcare system in Ghana. It discusses the public and private sector as well as traditional medical practice. It also discusses the country’s pharmaceutical industry. It is recommended as a companion to Professor Regina...
View Details
Keywords:
Africa;
Pharmaceutical Companies;
Pharmacy Benefit Manager;
Health Care;
Health Care Costs;
Health Care Delivery;
Health Care Entrepreneurship;
Telehealth;
Health Equity;
Governing Rules, Regulations, and Reforms;
Health Care and Treatment;
Business and Government Relations;
Health Industry;
Health Industry;
Ghana
Herzlinger, Regina E., and Ben Creo. "Note on Healthcare in Ghana." Harvard Business School Background Note 323-112, April 2023. (Revised January 2024.)